Allogeneic Cord Blood for Neurological Diseases in Adults

Allogeneic Cord Blood in the Treatment of Neurological Diseases in Adults

Status

Withdrawn

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05515419

Enrollment

Registered

2022-08-25

Start date

2025-07-01

Completion date

2026-11-30

Last updated

2025-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurological Diseases, Spinal Cord Injuries, Stroke

Keywords

Adults

Brief summary

This open label trial is conducted to investigate the efficacy and safety of allogeneic umbilical cord blood therapy for adult patients with neurological diseases.

Detailed description

Neurological diseases such as stroke or spinal cord injuries are very common etiologies causing disability in developed countries. Cord blood possess various stem and progenitor cells, as well as their secreted regenerative factors, and is known to repair injured brain. The investigators clinical research aims to determine the safety and efficacy of allogeneic Umbilical Cord Blood for adult patients with neurological diseases such as stroke and spinal cord injury.

Interventions

BIOLOGICALAllogeneic cord blood treatment

Allogeneic cord blood treatment

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

allogeneic cord blood for adult patients with neurological diseases

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Ischemic or hemorrhagic stroke (onset \< 24 months), or * Spinal cord injury (onset \< 24 months)

Exclusion criteria

* Raised intracranial pressure * Malignant cancer * Renal failure * Severe pulmonary dysfunction

Design outcomes

Primary

Measure	Time frame	Description
Changes in modified Rankin Scale (mRS)	1 month - 3 months - 6 months - 12 months	modified Rankin Scale (mRS) from 1 - 5 whereby 1 is best (no significant disability) and 5 is worst (severe disability); The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.

Secondary

Measure	Time frame	Description
Monitoring Adverse Events	1 month - 3 months - 6 months - 12 months	Number of participants with treatment-related adverse events as assessedCommon by Toxicity Criteria for Adverse Events (CTCAE).version 5.0; adverse events are graded on a scale from 0 to 5, whereby grade 0 is best (no AE) and grade 5 is worst (fatal).

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026